López-Cerdá S, Molinaro G, ParejaTello R, Correia A, Künig S, Steinberger P, et al.. Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid?Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Applied Materials & Interfaces [Internet]. 2024;16(15):18643 - 18657. https://pubs.acs.org/doi/10.1021/acsami.4c02363

Batchu KC, Hänninen S, Jha SK, Jeltsch M, Somerharju P. Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2016;1861(11):1597. 

Schaupper MV, Jeltsch M, Rohringer S, Redl H, Holnthoner W. Lymphatic Vessels in Regenerative Medicine and Tissue Engineering. Tissue Engineering Part B [Internet]. 2016;22(5):1-13. http://online.liebertpub.com/doi/10.1089/ten.TEB.2016.0034

Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-?-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstract

Jeltsch M, Jha SKumar, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, et al.. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstract

Anisimov A, Leppänen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al.. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. 

Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, et al.. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. 

Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, et al.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428

Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, et al.. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell [Internet]. 2010;18(6):630 - 40. http://view.ncbi.nlm.nih.gov/pubmed/21130043

Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974

Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, et al.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522

Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, et al.. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809

Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, et al.. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J [Internet]. 2006;20(9):1462 - 72. http://view.ncbi.nlm.nih.gov/pubmed/16816121

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292

Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al.. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol [Internet]. 2004;5(1):74 - 80. http://view.ncbi.nlm.nih.gov/pubmed/14634646

Saaristo A, Veikkola T, Enholm B, Hytönen M, Arola J, Pajusola K, et al.. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J [Internet]. 2002;16(9):1041 - 9. http://view.ncbi.nlm.nih.gov/pubmed/12087065

Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al.. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001;20(4):672 - 82. http://view.ncbi.nlm.nih.gov/pubmed/11179212

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103